Projects

• NEWTBVAC
• Pre- and early clinical development
• TBTEA
• MYCOWALC
• ADITEC
• TRANSVAC
• TBVI Advocacy & Resource Mobilisation
• TBVAC
• INYVAX
  • List of partners
• ESI TBVI

1. TBVI »
2. Projects »
3. INYVAX

February 2009 - February 2012
932,335 euro, funded by the European Commission under Framework Programme 7

TuBerculosis Vaccine Initiative was a partner in INYVAX, a project for the optimization of the development of vaccines against Poverty Related Diseases (PRD) that was succesfully closed in February 2012.

The development of PRD vaccines faces several common gaps and challenges, including:

• difficulties in accessing know-how and technology platforms in vaccine development, formulation, and delivery;
• difficulties in harmonizing safety data collection;
• insufficient number of trained scientists able to undertake leadership roles in vaccine development.

INYVAX addressed these common gaps and challenges by:

1. Establishing a comprehensive database of marketed PRD vaccines and vaccines in development, addressing the advantages, constraints and limits of each technologies and additional criteria such as transferability of the know-how, benchmarking, production costs or regulatory compliance;
   
   
2. Optimizing knowledge and resources for the formulation of PRD vaccines;
   
   
3. Implementing safety standards in clinical trials of PRD vaccines, allowing meta-analysis of the safety of similar vaccine approaches;
   
   
4. Establishing a training program in vaccinology, including: Pre-clinical vaccine research, Design and monitoring of clinical trials, Vaccine safety issues, Selection of new and appropriate vaccination strategies and Effective communication.

In the project, different groups of PRD vaccine developers, in total 8 partners,  cooperated to bring innovative approaches for accelerating the development of effective vaccines. The European Vaccine Initiative (EVI) coordinated this 3 year project. TBVI director Jelle Thole was a member of the INYVAX Steering Committee.